以盐酸米托蒽醌脂质体为基础的化疗方案治疗髓系肉瘤的效果与安全性分析
Efficacy and safety analyses of mitoxantrone hydrochloride liposome-based chemotherapy regimens for treatment of myeloid sarcoma
摘要
目的:探讨以新型蒽环类制剂盐酸米托蒽醌脂质体(Lipo-MIT)为基础的化疗方案对髓系肉瘤诱导缓解的疗效与安全性。方法:回顾性病例系列研究。收集中国医学科学院血液病医院2023年2月至2024年6月收治并经病理检查确诊的6例髓系肉瘤患者资料。患者均接受以Lipo-MIT为基础的方案诱导治疗,其中4例采用MAV方案(维奈克拉+阿扎胞苷+Lipo-MIT),1例采用MA方案(Lipo-MIT+阿糖胞苷),1例采用AM方案(阿扎胞苷+Lipo-MIT)。评估患者治疗反应及不良事件发生情况。结果:6例髓系肉瘤患者中,男性3例,女性3例;中位年龄为34.5岁(范围:28~39岁)。除1例接受根治性切除的患者,其余5例可评估患者中,4例达完全缓解(CR),其中3例于1个疗程后达CR,1例于2个疗程后达CR;另1例多次复发、对既往放疗和常规化疗无效的患者,经单周期Lipo-MIT为基础的方案治疗后病情稳定。主要血液学不良反应为3~4级,4例发生发热性中性粒细胞减少,治疗后恢复。结论:以Lipo-MIT为基础的诱导治疗方案对髓系肉瘤具有较好的疗效和可接受的安全性,联合阿扎胞苷与维奈克拉可能进一步提高疗效。
Objective:To evaluate the efficacy and safety of chemotherapy regimens based on novel anthracycline formulation mitoxantrone hydrochloride liposome (Lipo-MIT) for induction remission of myeloid sarcoma.Methods:A retrospective case series was conducted. Data were collected from 6 myeloid sarcoma patients who were admitted to the Blood Diseases Hospital of Chinese Academy of Medical Sciences from February 2023 to June 2024 and confirmed by pathology test. All patients received induction therapy with the Lipo-MIT-based regimens: 4 patients were treated with the MAV regimen (venetoclax+azacitidine+Lipo-MIT), 1 patient received the MA regimen (Lipo-MIT+cytarabine), and one patient was assigned to the AM regimen (azacitidine+Lipo-MIT). Treatment response and adverse events were assessed.Results:Among the 6 myeloid sarcoma patients, 3 were male and 3 were female, with a median age of 34.5 years (range: 28-39 years). With the exception of 1 patient who underwent curative resection, among the remaining 5 evaluable patients, 4 achieved complete remission (CR), 3 after one cycle and 1 after two cycles, while another patient, who had experienced multiple relapses and was refractory to prior radiotherapy and conventional chemotherapy, achieved disease stabilization following a single cycle of the Lipo-MIT-based regimen. The major hematologic adverse events were grade 3-4; 4 patients developed febrile neutropenia, which resolved after treatment.Conclusions:The induction regimens based on Lipo-MIT demonstrate favorable efficacy and acceptable safety in myeloid sarcoma, and combination with azacitidine and venetoclax may further enhance therapeutic outcomes.
年,卷(期):
2026, 35(7)
在线出版日期:
2026年7月25日